Postremission therapy for acute myeloid leukemia in the first remission

The medical records of 99 patients with acute myeloid leukemia (AML; except AML, M3) in the first remission from 1995 to 2004 were retrospectively reviewed. When they achieved complete remission, at first complete remission (CR1), patients received allogeneic (n = 23), autologous hematopoietic stem...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2007-01, Vol.48 (5), p.937-943
Main Authors: Kim, Seung Tai, Jung, Chul Won, Lee, Jeeyun, Kwon, Jung Mi, Oh, Sung Young, Park, Byeong-Bae, Lee, Hyo Rak, Kim, Hyun Jung, Kim, Kihyun, Kim, Won Seog, Ahn, Jin Seok, Kang, Won Ki, Park, Keunchil
Format: Article
Language:English
Subjects:
Adult
allogeneic
AML
Antineoplastic Agents - therapeutic use
autologous HSCT
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation - methods
Humans
intensive chemotherapy
Leukemia, Myeloid, Acute - pathology
Leukemia, Myeloid, Acute - therapy
Male
Middle Aged
postremission therapy
Prognosis
Remission Induction
Retrospective Studies
Time Factors
Transplantation, Homologous
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The medical records of 99 patients with acute myeloid leukemia (AML; except AML, M3) in the first remission from 1995 to 2004 were retrospectively reviewed. When they achieved complete remission, at first complete remission (CR1), patients received allogeneic (n = 23), autologous hematopoietic stem cell transplantation (HSCT) (n = 35), or intensive chemotherapy (n = 41) according to prognostic factors and donor availability. There was an advantage in terms of event-free survival (EFS, p = 0.0001) and overall survival (OS, p = 0.0002) with HSCT as compared to those of intensive chemotherapy. However, the EFS and OS were not different between allogeneic HSCT and autologous HSCT. In high-risk patients, the EFS and OS of allogenic or autologous HSCT group were higher compared with those in the intensive chemotherapy group (p < 0.01). However, there was no difference between allogeneic HSCT and autologous HSCT in terms of EFS and OS. In the intermediate- or low-risk group, there was no significant difference in the outcome according to the postremission modalities.
ISSN:1042-8194
1029-2403
DOI:10.1080/10428190701223309